H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10

H.C. Wainwright analyst Robert Burns maintains $Zymeworks(ZYME.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 0.0% and a t

Futu NewsJun 18 18:31 · Ratings

Zymeworks Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 17.1% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/06/2024 17.1% HC Wainwright & Co. $

BenzingaJun 18 18:12

Zymeworks ZW171 IND for Mesothelin-expressing Cancers Cleared by FDA

Seeking AlphaJun 18 02:49

Market-Moving News for June 17th

BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171

BenzingaJun 17 20:40

Express News | Zymeworks Shares up 4.1% Premarket After FDA Clears Co's Application to Start Trials in Humans for Cancer Drug

BreakingsJun 17 19:05

Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers

By Colin Kellaher Zymeworks has won Food and Drug Administration approval to begin studies of ZW171, a bispecific antibody targeting mesothelin-expressing cancers. The Middletown, Del., clinical-sta

WSJJun 17 18:19